Transaction · 0001193125-26-092157

Guyer William

Guyer William, CDO, reported a transaction classified as grant at CORCEPT THERAPEUTICS INC involving 498.000000 shares for an estimated $17913.06. Reported holdings after the transaction were 1733.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACDO
CORTCORCEPT THERAPEUTICS INC
Filing timeMar 04
Trade dateMar 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$35.69
Pre-filing
1mo ago +11.7%1w ago -1.0%1d ago +0.0%
Returns since
7d -5.5%30d +19.1%90d +99.5%180d +244.0%1y +244.0%

CORT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CORT since 2026-03-04Filed 184 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001193125-26-092157
Common Stock
Transaction date
Mar 02, 2026
Filed Mar 04, 2026, 12:00 AM · 2d delay
Shares
498 sh
$3.59k per share
Estimated value
$1.79M
Computed from shares × price
Holdings after
1.73k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Increase
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Development Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…

  2. F2

    In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

  3. F3

    Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest o…

  4. F4

    Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…

Original filing · 0001193125-26-092157
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CORT